For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.


  • December

  • November

    Highlighted Articles

  • May

    Highlighted Articles

    • Drexel Dragon

      Drexel University Spinout Raises $4M for Voltage-Activated Heart Imaging Drug

      May 26, 2021

      A drug development company attempting to commercialize a high-tech imaging agent developed by researchers and physicians at Drexel University has raised $4 million.

      Read More

    • Kinos Medical Inc.

      Kinos Medical Merges with restor3d

      May 14, 2021

      Kinos was founded in 2017 to translate and commercialize Coulter Foundation funded biomechanics research, led by professor Sorin Siegler, Ph.D. Together as an interdisciplinary team of clinical thought leaders, engineers, scientists, and investors, "Kinos is focused on improving the surgical options available to preserve motion in patients with ankle arthritis. The Axiom total ankle is the first biomechanically accurate implant on the market, offering motion in all three anatomic planes, as is seen in the natural ankle," said Brian Garvey, CEO of Kinos Medical. "We are thrilled to partner with the restor3d team to combine our advanced technologies into a holistic product offering."

      Read More

  • April

    Highlighted Articles

    • Medical Device Startup Nephria Bio to Use Drexel's MXene Filter Material in Wearable Artificial Kidney Technology

      April 29, 2021

      <p style="margin: 0in;">Drexel University&rsquo;s MXene material is one step closer to transforming the lives of people suffering from end-stage kidney disease. Nephria Bio, Inc., a U.S.-based spin-off of the South Korean medical device company EOFlow Co., Ltd., has signed a licensing agreement with the University to use the two-dimensional material, discovered at Drexel, as a filter in a wearable artificial kidney device it is developing. The technology could allow many of the millions of people suffering from end-stage kidney disease worldwide to move more freely, without spending hours each week anchored to large dialysis machines.</p>
      <p style="margin: 0in;">&nbsp;</p>

      Read More

    • Rain Therapeutics Inc.

      Rain Therapeutics Announces Pricing of Initial Public Offering

      April 22, 2021

      Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public offering of 7,352,941 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Rain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rain, are expected to be approximately $125.0 million. All of the shares are being offered by Rain. The shares are expected to begin trading on The Nasdaq Global Select Market on April 23, 2021 under the ticker symbol “RAIN.” In addition, Rain has granted the underwriters a 30-day option to purchase up to an additional 1,102,941 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021 subject to the satisfaction of customary closing conditions.

      Read More